Genetic mutation

New data from the phase 1 CHRYSALIS study, which has evaluated Amivantamab in patients with metastatic or unresectable non-small cell...


The U.S. Food and Drug Administration ( FDA ) has approved Lumakras ( Sotorasib ) as the first treatment for...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Scemblix ( Asciminib ) for patients with...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...


Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


The FDA ( U.S. Food and Drug Administration ) has approved Tagrisso ( Osimertinib ) as the first adjuvant treatment...


The FDA ( U.S. Food and Drug Administration ) has approved Onureg ( Azacitidine 300 mg tablets, CC-486 ) for...


Positive results from the randomized phase 2 ELEKTRA study of Soticlestat in children with Dravet syndrome ( DS ) or...


The FDA ( U.S. Food and Drug Administration ) has approved Koselugo ( Selumetinib ) for the treatment of pediatric...


The FDA ( Food and Drug Administration ) has approved Gavreto ( Pralsetinib ) for the treatment of adults with...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Rozlytrek ( Entrectinib ), a treatment...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Balversa ( Erdafitinib ), a treatment...


The U.S. Food and Drug Administration ( FDA ) has approved Zolgensma ( Onasemnogene abeparvovec-xioi ), the first gene therapy...


The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with...


Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy ( BKI ) released a...


Week 48 results from phase III TANGO study were announced. The TANGO study was conducted to assess whether adults living...


Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only...


The FDA ( U.S. Food and Drug Administration ) has approved Tibsovo ( Ivosidenib ) tablets for the treatment of...


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met...